by admin_63069 | Mar 17, 2025 | News You Can Use
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.
by admin_63069 | Mar 12, 2025 | Related Topics
Variants in fewer than 1% of tumors, possibly suggesting need to revisit treatment guidelines
by admin_63069 | Mar 10, 2025 | News You Can Use
Clearance of all visible prostate lesions at 6 months in five treated patients.
by admin_63069 | Mar 3, 2025 | News You Can Use
Advancing prostate cancer science through clinical trials and powerful data
